Myriad Genetics entered into an agreement with CancerCARE for Life to provide individuals within the latter's network with access to the MyRisk Hereditary Cancer Test.

Updated Screening Guidelines Ensure Broader Access to Colorectal Cancer Screening in GermanyBERKELEY, Calif. and MAINZ, ...

The ability to predict spirometry-defined COPD was significantly better when a modified lung function questionnaire score was ...

Conservative supporters of government deregulation want to do away with state-imposed licensing requirements, a move genetic counselors say will harm patients.

KBC Group NV raised its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 132.8% in the fourth quarter, ...

GAITHERSBURG, Md. - GeneDx (NASDAQ: WGS), a genomic insights company valued at $1.64 billion, has launched its services on Aura, Epic's specialty diagnostics suite, to facilitate advanced genetic ...

As a trailblazer in the world of sports journalism, Hannah Storm has always known exactly what to say on camera. But when she received a breast cancer diagnosis in January 2024, the legendary ...

Genetic testing has become an asset in today’s society, which values personalized healthcare more than before. By delving into one’s composition, individuals can not only gauge potential health ...

In a recent study, Mass General Brigham researchers demonstrated that through low-cost genetic samples that can be obtained from a cheek swab or blood test, they can improve identification of people ...

SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc.

Myriad Genetics (MYGN) and INTERLINK Care Management announced an agreement designed to enhance education and access to hereditary cancer ...

The Foundation Medicine next-generation sequencing-based panels use Fulgent's technology platform and will analyze genes associated with hereditary cancers.